A pilot study on the effects of early use of valproate sodium on neuroinflammation after traumatic brain injury.
10.7499/j.issn.1008-8830.2210136
- Author:
Zhi LIU
1
;
Lei ZHU
1
;
Li-Ping SHENG
1
;
Qing-Chen HUANG
1
;
Tong QIAN
1
;
Bo-Xiang QI
1
Author Information
1. Xuzhou Children's Hospital Affiliated to Xuzhou Medical University, Xuzhou, Jiangsu 221006, China.
- Publication Type:Journal Article
- Keywords:
Child;
Neuroinflammation;
Sodium valproate;
Traumatic brain injury
- MeSH:
Child;
Humans;
Valproic Acid/therapeutic use*;
HMGB1 Protein;
Pilot Projects;
Tumor Necrosis Factor-alpha;
Neuroinflammatory Diseases;
NLR Family, Pyrin Domain-Containing 3 Protein;
Prospective Studies;
Brain Injuries, Traumatic/pathology*
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(3):253-258
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To study the effect of early use of sodium valproate on neuroinflammation after traumatic brain injury (TBI).
METHODS:A total of 45 children who visited in Xuzhou Children's Hospital Affiliated to Xuzhou Medical University from August 2021 to August 2022 were enrolled in this prospective study, among whom 15 healthy children served as the healthy control group, and 30 children with TBI were divided into a sodium valproate treatment group and a conventional treatment group using a random number table (n=15 each). The children in the sodium valproate treatment group were given sodium valproate in addition to conventional treatment, and those in the conventional group were given an equal volume of 5% glucose solution in addition to conventional treatment. The serum concentrations of nucleotide-binding oligomerization domain-like receptor protein 3(NLRP3), high-mobility group box 1 (HMGB1), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) were measured in the healthy control group on the day of physical examination and in the children with TBI on days 1, 3, and 5 after admission. Glasgow Outcome Scale-Extended (GOS-E) score was evaluated for the children with TBI 2 months after discharge.
RESULTS:Compared with the healthy control group, the children with TBI had significantly higher serum concentrations of NLRP3, HMGB1, TNF-α, and IL-1β on day 1 after admission (P<0.017). The concentration of NLRP3 on day 5 after admission was significantly higher than that on days 1 and 3 after admission in the children with TBI (P<0.017). On days 3 and 5 after admission, the sodium valproate treatment group had a significantly lower concentration of NLRP3 than the conventional treatment group (P<0.05). For the conventional treatment group, there was no significant difference in the concentration of HMGB1 on days 1, 3, and 5 after admission (P>0.017), while for the sodium valproate treatment group, the concentration of HMGB1 on day 5 after admission was significantly lower than that on days 1 and 3 after admission (P<0.017). On day 5 after admission, the sodium valproate treatment group had a significantly lower concentration of HMGB1 than the conventional treatment group (P<0.05). For the children with TBI, the concentration of TNF-α on day 1 after admission was significantly lower than that on days 3 and 5 after admission (P<0.017). On days 3 and 5 after admission, the sodium valproate treatment group had a significantly lower concentration of TNF-α than the conventional treatment group (P<0.05). The concentration of IL-1β on day 3 after admission was significantly lower than that on days 1 and 5 after admission (P<0.017) in the children with TBI. On days 3 and 5 after admission, the sodium valproate treatment group had a significantly lower concentration of IL-1β than the conventional treatment group (P<0.05). The GOS-E score was significantly higher in the sodium valproate treatment group than that in the conventional treatment group 2 months after discharge (P<0.05).
CONCLUSIONS:Early use of sodium valproate can reduce the release of neuroinflammatory factors and improve the prognosis of children with TBI.
